Thousand Oaks Biopharmaceuticals Co., Ltd. reaches strategic partnership with Biotheus

On August 14, 2020, Thousand Oaks Biopharmaceuticals Co., Ltd. and Biotheus Biotechnology Co., Ltd. ("Biotheus") established a strategic framework partnership in the Hi-park in Haimen, by which both agreed to cooperate comprehensively on custom & contract development and production - from IND application to clinical sample production - for a number of antibody projects of the latter.

As agreed in the transaction, Thousand Oaks Biopharmaceuticals Co., Ltd. will provide Biotheus with integrated services for its innovative antibody drugs, ranging from process development to IND application and to drug production in the clinical phases. With its world-class technical team, professional and sophisticated technology platform, and rich experience in project development and management, Thousand Oaks Biopharmaceuticals Co., Ltd. finds itself qualified to spur the development of the first-in-class biologics of Biotheus, so that high-quality innovative drugs could be applied to more patients sooner.

Biotheus’ core research areas include tumor immunotherapy, metabolic disease treatment, and other common or incurable diseases. Its core team has been engaged in a total of over 40 new drug development projects, and is currently proceeding with more than 10 national first-in-class biopharmaceutical drug projects, including monoclonal antibodies and bispecific antibodies.

Dr Zuoyu Sun, Co-founder and Senior VP of Biotheus, said: “Thousand Oaks Biopharmaceuticals Co., Ltd. has a very good reputation in the industry and has served dozens of Chinese and foreign customers. Some of these projects have been successfully approved in the FDA/NMPA IND applications. Its subsidiary JSBiosciences enables it to acquire industry-approved process development capabilities. It is indeed a first-rate biomacromolecule CDMO company in China that delivers cell culture media formulation development capabilities, and experienced commercial manufacturing in compliance with regulatory standards. They are very competitive within the Triple Constraint: quality, speed and cost."

Dr Shun Luo, Chairman and President of Thousand Oaks Biopharmaceuticals Co., Ltd., said: "I am very glad to reach a consensus on the cooperation with Biotheus, which is known for its innovation. In the cooperation with Biotheus, we will use our strong technical strength to provide high-quality CMC services, comprehensively assist the partner to get the clinical approval sooner and with high quality, and accelerate the process of commercial production, to therefore benefit the patients as soon as possible."